ASND vs. BDX: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ASND and BDX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
BDX’s market capitalization of 50.49 billion USD is significantly greater than ASND’s 10.52 billion USD, highlighting its more substantial market valuation.
With betas of 0.36 for ASND and 0.28 for BDX, both stocks show similar sensitivity to overall market movements.
ASND trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, BDX is a standard domestic listing.
| Symbol | ASND | BDX |
|---|---|---|
| Company Name | Ascendis Pharma A/S | Becton, Dickinson and Company |
| Country | DK | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Instruments & Supplies |
| CEO | Jan Moller Mikkelsen | Thomas E. Polen Jr. |
| Price | 174.18 USD | 176.16 USD |
| Market Cap | 10.52 billion USD | 50.49 billion USD |
| Beta | 0.36 | 0.28 |
| Exchange | NASDAQ | NYSE |
| IPO Date | January 28, 2015 | February 21, 1973 |
| ADR | Yes | No |
Historical Performance
This chart compares the performance of ASND and BDX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ASND
191.42%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
ASND’s Return on Equity of 191.42% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
BDX
5.86%
Medical - Instruments & Supplies Industry
- Max
- 26.65%
- Q3
- 13.00%
- Median
- 1.08%
- Q1
- -8.11%
- Min
- -38.20%
BDX’s Return on Equity of 5.86% is on par with the norm for the Medical - Instruments & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
ASND
-50.64%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
ASND has a negative Return on Invested Capital of -50.64%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.
BDX
4.35%
Medical - Instruments & Supplies Industry
- Max
- 20.14%
- Q3
- 7.36%
- Median
- 1.97%
- Q1
- -6.22%
- Min
- -20.00%
BDX’s Return on Invested Capital of 4.35% is in line with the norm for the Medical - Instruments & Supplies industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
ASND
-92.67%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
ASND has a negative Net Profit Margin of -92.67%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
BDX
7.18%
Medical - Instruments & Supplies Industry
- Max
- 28.95%
- Q3
- 11.24%
- Median
- -2.83%
- Q1
- -12.85%
- Min
- -26.41%
BDX’s Net Profit Margin of 7.18% is aligned with the median group of its peers in the Medical - Instruments & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ASND
-90.54%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
ASND has a negative Operating Profit Margin of -90.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
BDX
11.33%
Medical - Instruments & Supplies Industry
- Max
- 32.10%
- Q3
- 16.03%
- Median
- 2.28%
- Q1
- -7.96%
- Min
- -26.84%
BDX’s Operating Profit Margin of 11.33% is around the midpoint for the Medical - Instruments & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ASND | BDX |
|---|---|---|
| Return on Equity (TTM) | 191.42% | 5.86% |
| Return on Assets (TTM) | -32.19% | 2.75% |
| Return on Invested Capital (TTM) | -50.64% | 4.35% |
| Net Profit Margin (TTM) | -92.67% | 7.18% |
| Operating Profit Margin (TTM) | -90.54% | 11.33% |
| Gross Profit Margin (TTM) | 85.30% | 44.50% |
Financial Strength
Current Ratio
ASND
1.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ASND’s Current Ratio of 1.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
BDX
1.13
Medical - Instruments & Supplies Industry
- Max
- 6.79
- Q3
- 4.57
- Median
- 2.64
- Q1
- 1.81
- Min
- 1.10
BDX’s Current Ratio of 1.13 falls into the lower quartile for the Medical - Instruments & Supplies industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
ASND
-4.46
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
ASND has a Debt-to-Equity Ratio of -4.46, which indicates negative shareholder equity where liabilities exceed assets. This is a critical sign of financial distress.
BDX
0.76
Medical - Instruments & Supplies Industry
- Max
- 1.46
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.16
- Min
- 0.03
BDX’s leverage is in the upper quartile of the Medical - Instruments & Supplies industry, with a Debt-to-Equity Ratio of 0.76. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio
ASND
-3.72
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
ASND has a negative Interest Coverage Ratio of -3.72. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
BDX
3.95
Medical - Instruments & Supplies Industry
- Max
- 25.04
- Q3
- 8.80
- Median
- 3.66
- Q1
- -3.85
- Min
- -11.93
BDX’s Interest Coverage Ratio of 3.95 is positioned comfortably within the norm for the Medical - Instruments & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ASND | BDX |
|---|---|---|
| Current Ratio (TTM) | 1.04 | 1.13 |
| Quick Ratio (TTM) | 0.71 | 0.64 |
| Debt-to-Equity Ratio (TTM) | -4.46 | 0.76 |
| Debt-to-Asset Ratio (TTM) | 0.80 | 0.35 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.34 | 5.29 |
| Interest Coverage Ratio (TTM) | -3.72 | 3.95 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ASND and BDX. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ASND
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ASND currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
BDX
2.31%
Medical - Instruments & Supplies Industry
- Max
- 4.02%
- Q3
- 0.38%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 2.31%, BDX offers a more attractive income stream than most of its peers in the Medical - Instruments & Supplies industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
ASND
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ASND has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
BDX
76.77%
Medical - Instruments & Supplies Industry
- Max
- 76.77%
- Q3
- 11.37%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BDX’s Dividend Payout Ratio of 76.77% is in the upper quartile for the Medical - Instruments & Supplies industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | ASND | BDX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.31% |
| Dividend Payout Ratio (TTM) | 0.00% | 76.77% |
Valuation
Price-to-Earnings Ratio
ASND
-25.98
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ASND has a negative P/E Ratio of -25.98. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.
BDX
33.92
Medical - Instruments & Supplies Industry
- Max
- 45.65
- Q3
- 44.10
- Median
- 35.47
- Q1
- 29.60
- Min
- 21.65
BDX’s P/E Ratio of 33.92 is within the middle range for the Medical - Instruments & Supplies industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Forward P/E to Growth Ratio
ASND
-2.36
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ASND has a negative Forward PEG Ratio of -2.36. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
BDX
5.98
Medical - Instruments & Supplies Industry
- Max
- 5.80
- Q3
- 3.68
- Median
- 2.56
- Q1
- 1.87
- Min
- 0.22
BDX’s Forward PEG Ratio of 5.98 is exceptionally high for the Medical - Instruments & Supplies industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.
Price-to-Sales Ratio
ASND
24.22
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
ASND’s P/S Ratio of 24.22 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
BDX
2.42
Medical - Instruments & Supplies Industry
- Max
- 12.87
- Q3
- 6.95
- Median
- 3.45
- Q1
- 2.24
- Min
- 0.71
BDX’s P/S Ratio of 2.42 aligns with the market consensus for the Medical - Instruments & Supplies industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ASND
-46.77
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
BDX
2.01
Medical - Instruments & Supplies Industry
- Max
- 9.60
- Q3
- 5.48
- Median
- 3.37
- Q1
- 1.95
- Min
- 0.65
BDX’s P/B Ratio of 2.01 is within the conventional range for the Medical - Instruments & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ASND | BDX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -25.98 | 33.92 |
| Forward PEG Ratio (TTM) | -2.36 | 5.98 |
| Price-to-Sales Ratio (P/S, TTM) | 24.22 | 2.42 |
| Price-to-Book Ratio (P/B, TTM) | -46.77 | 2.01 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -29.03 | 19.49 |
| EV-to-EBITDA (TTM) | -37.74 | 19.65 |
| EV-to-Sales (TTM) | 25.11 | 3.31 |